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Abstract
Prognosis and therapeutic management of dogs with cutaneous mast cell tumors (MCTs) depend on clinical stage and
histological grade. However, the prognostic value of this latter is still questionable. In the present study, MCT transcriptome
was analyzed to identify a set of candidate genes potentially useful for predicting the biological behavior of MCTs. Fifty-one
canine MCT biopsies were analyzed. Isolated and purified total RNAs were individually hybridized to the Agilent Canine V2
4x44k DNA microarray. The comparison of reference differentiated and undifferentiated MCT transcriptome revealed a total
of 597 differentially expressed genes (147 down-regulated and 450 up-regulated). The functional analysis of this set of
genes provided evidence that they were mainly involved in cell cycle, DNA replication, p53 signaling pathway, nucleotide
excision repair and pyrimidine metabolism. Class prediction analysis identified 13 transcripts providing the greatest
accuracy of class prediction and divided samples into two categories (differentiated and undifferentiated), harboring a
different prognosis. The Principal Component Analysis of all samples, made by using the selected 13 markers, confirmed
MCT classification. The first three components accounted for 99.924% of the total variance. This molecular classification
significantly correlated with survival time (p= 0.0026). Furthermore, among all marker genes, a significant association was
found between mRNA expression and MCT-related mortality for FOXM1, GSN, FEN1 and KPNA2 (p,0.05). Finally, marker
genes mRNA expression was evaluated in a cohort of 22 independent samples. Data obtained enabled to identify MCT cases
with different prognosis. Overall, the molecular characterization of canine MCT transcriptome allowed the identification of a
set of 13 transcripts that clearly separated differentiated from undifferentiated MCTs, thus predicting outcome regardless of
the histological grade. These results may have clinical relevance and warrant future validation in a prospective study.
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Introduction
Nowadays, molecular profiling technologies provide the poten-
tial to comprehend relevant biological networks underlying the
cellular and molecular origin of cancer as well as to tailor medical
care, both at tumor and patient levels [1,2]. Gene expression
profiling has shown a great potential in cancer research, providing
a detailed view on the molecular changes involved in tumor
progression, leading to a better understanding of the pathophys-
iological process, discovering new prognostic markers and novel
therapeutic targets [1].
An increasing number of –omic oncologic studies have been
recently published in the dog, focusing on mammary tumor
[3,4,5,6], hemangiosarcoma [7], osteosarcoma [8,9,10], lympho-
ma [11,12], urinary bladder cancer [13], histiocytic sarcoma [14]
and melanoma [15]. Conversely, the transcriptome of canine
cutaneous mast cell tumor (MCT) has not been characterized so
far, although MCTs are frequent tumors in dogs, accounting for
approximately 6% of all canine neoplasms and 20% of all skin
tumors [16,17].
Unlike human cutaneous mastocytosis, that is rare and benign
[18], the disease course of canine MCT may be aggressive [17].
Currently, therapy is mainly guided by histological grade and
clinical stage, which have prognostic relevance [19,20]. Neverthe-
less, the prognostic value of the histological grading is still
questionable, particularly for Patnaik grade 2 (G2) MCTs. Indeed,
while the biological behavior for Patnaik-G1 and Patnaik-G3
MCTs can generally be anticipated, the prognosis for Patnaik-G2
MCTs is variable [17]. In addition to the unpredictable behavior
of Patnaik-G2 MCTs, histopathological grading is subjective,
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resulting in grading variations among pathologists [21,22]. In
2011, a new grading system was proposed by Kiupel and
coauthors, aiming at improving concordance among pathologists
[20]. This two-tier histologic grading system was demonstrated to
be more accurate at predicting metastasis development and tumor
mortality than the Patnaik system [20]. Nevertheless, approxi-
mately 15% of dogs with Kiupel low grade MCTs have nodal
involvement at presentation (Marconato, personal data), indicating
that also this grading system possesses some gaps.
The aim of the present study was to characterize the MCT
transcriptome by using DNA microarray technology, in order to
define a fingerprint of aggressiveness that could predict the
biological behavior, possibly overcoming the pitfalls of histological
grading.
Materials and Methods
Ethics Statements
Animal care, surgery and post surgery were carried out in
accordance with good veterinary practices; dogs were under the
care of licensed veterinarians and participation in the study did not
influence decisions of care. According to the Italian law (D. Lgs. n.
116/92), an Institutional Animal Care and Use Committee
approval number and date of approval for the study are not
requested for both academia and private practice. Only a written
informed consent is needed to conduct a clinical trial.
Tumor Samples
In this prospective study, seventy-three histologically confirmed
samples of spontaneous canine cutaneous MCTs were collected
from veterinary clinics of Northern Italy throughout the years
2007–2013, during routine diagnostic or therapeutic surgical
procedure and after written informed consent of the owner.
Aliquots from the central part of the tumor mass (up to 100 mg
each) were aseptically collected, immediately stored in RNAlater
solution (Life Technologies, Foster City, CA) and kept at –20uC
until use.
For each included case, the following data were retrieved from
medical records: breed, age, sex, grade according to Patnaik’s
system and Kiupel’s [19,20], type of treatment (surgery, radiation
therapy, chemotherapy, tyrosine kinase inhibitors or a combina-
tion of these), survival time, and cause of death.
MCTs from 51 dogs yielded high quality total RNA and passed
the quality control for gene expression profiling on DNA
microarrays. The remaining 22 samples were used in quantitative
Real Time PCR (qPCR) confirmatory analyses.
For sample class prediction, 18 out of the 51 samples used for
gene expression profiling were chosen as ‘‘reference samples’’ on
the basis of Patnaik and Kiupel histological classification and
mitotic index; these ‘‘reference samples’’ included 13 ‘‘differenti-
ated MCTs’’ (Patnaik-G1 or G2 and Kiupel low grade [L], with a
mitotic index#5), and 5 ‘‘undifferentiated MCTs’’ (Patnaik-G2 or
G3, Kiupel high grade [H], with a mitotic index .5). The choice
Table 1. DNA microarray validation: Spearman correlation analysis of normalized DNA microarray data and corresponding qPCR
results for the whole set of samples.
Target gene Spearman R
CCNB2 (probe 1) 0.9306***
CCNB2 (probe 2) 0.9281***
CCNB2 (probe 3) 0.9103***
CDC20 0.9158***
CDCA8 0.9241***
CENPP 0.7348***
FEN1 0.7797***
FOXM1 (probe 1) 0.8014***
FOXM1 (probe 2) 0.8571***
GSN (probe 1) 0.8228***
GSN (probe 2) 0.9256***
GSN (probe 3) 0.9059***
KPNA2 (probe 1) 0.5392***
KPNA2 (probe 2) 0.6434***
NUF2 (probe 1) 0.8869***
NUF2 (probe 2) 0.9538***
NUF2 (probe 3) 0.9453***
NUSAP1 0.8851***
PRC1 (probe 1) 0.9650***
PRC1 (probe 2) 0.9439***
RAD51 0.9075***
UBE2S (probe 1) 0.5951***
UBE2S (probe 2) 0.7484***
UBE2S (probe 3) 0.7752***
***p,0.001; statistical analysis was performed for each target gene-specific probe available on the array.
doi:10.1371/journal.pone.0095481.t001
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of MCT reference samples was based on a 100% concordance
among all pathologists.
RNA Isolation and Purification
Total RNA was isolated from tissue specimens as previously
described [23] and subsequently purified using the RNeasy Mini
kit (Qiagen, Milan, Italy), according to the manufacturer’s
instructions. To avoid genomic DNA contaminations, on-column
DNase digestion with the RNase-free DNase set (Qiagen, Milan,
Italy) was performed. Total RNA concentration was determined
using the NanoDrop ND-1000 UV-Vis spectrophotometer (Na-
noDropTechnologies, Wilmington, DE), and quality was mea-
sured by using the 2100 Bioanalyzer and RNA 6000 Nano kit
(Agilent Technologies, Santa Clara, CA). All 51 samples included
in the gene expression profiling experiment were suitable for
microarray analysis based on RNA quality (RIN$7.0).
RNA Amplification, Labeling and Array Hybridization
Sample amplification, labeling and hybridization were per-
formed following the Agilent One-Color Microarray-Based Gene
Expression Analysis protocol. Briefly, for each individual sample,
100 ng of total RNA were linearly amplified and labeled with
Cy3-dCTP using Agilent Low Input Quick Amp Labeling kit
(Agilent Technologies, Santa Clara, CA) according to the
manufacturer’s instructions. A mixture of 10 different viral poly-
adenylated RNAs (Spike-In Mix, Agilent Technologies, Santa
Clara, CA) was added to each RNA sample before amplification
and labeling, to monitor microarray analysis work-flow. Labeled
cRNA was purified with RNeasy Mini Kit (Qiagen, Milan, Italy),
and sample concentration and specific activity (pmol Cy3/mg
cRNA) were measured with a NanoDrop ND-1000 UV-Vis
spectrophotometer. A total of 1.65 micrograms of labeled cRNA
was fragmented by using the Gene Expression Hybridization kit
(Agilent, Santa Clara, CA) following the manufacturer’s instruc-
tions. A volume of 100 mL of hybridization solution was then
dispensed in the gasket slide and assembled to the microarray slide,
with each slide containing four arrays. Canine-specific oligo-arrays
(Canine V2 4x44k G2519F, Design ID 021193, Agilent Technol-
ogies, Santa Clara, CA) were used. Slides were incubated for 17 h
at 65uC in an Hybridization Oven (Agilent Technologies, Santa
Clara, CA), subsequently removed from the hybridization
chamber, quickly submerged in GE Wash Buffer 1 to disassembly
slides and then washed in GE Wash Buffer 1 for approximately 1
minute, followed by one additional wash in pre-warmed (37uC)
GE Wash Buffer 2. Hybridized slides were scanned at 5 mm
resolution using a G2565BA DNA microarray scanner (Agilent
Technologies, Santa Clara, CA). Default settings were modified in
order to scan the same slide twice at two different sensitivity levels
(XDR Hi 100% and XDR Lo 10%). Total RNA of 4 samples was
labeled twice and hybridized separately in different slides to
generate technical replicates.
Microarray data have been deposited in NCBI’s Gene
Expression Omnibus, and are accessible through GEO Series
accession number GSE50433.
Normalization of Microarray Data
The two linked images generated from the scanned slide were
analyzed together, data were extracted and background subtracted
by using the standard procedures contained in the Agilent Feature
Extraction Software version 9.5.1. All 51 samples were then
normalized together in a single run to avoid potential biases.
Normalization procedures were performed by means of the R
statistical software (http://www.r-project.org), and by using Spike-
In control intensities to identify the best normalization procedure.
Normalization using limma package always yielded better results
than cyclic loess normalization, thus quantile-normalized data
were used in all subsequent analysis. After normalization, spike
intensities are expected to be uniform across the experiments of a
given dataset. All control features and Spike-in were excluded
from subsequent analyses. Missing values (probes with Feature
Extraction flag equal to 0) were imputed by using the microarray
data analysis tool TIGR Multiple Array Viewer (TMEV) [24].
Statistical Analyses
To identify differentially expressed genes between ‘‘reference
samples’’ (differentiated and undifferentiated MCTs), a two-class
Table 2. DAVID functional annotation of the complete list of differentially regulated genes between differentiated and
undifferentiated MCTs.
Category Term Count p value Fold Enrichment
GO_BP_FAT GO:0000279,M phase 3 5.00E-03 2.28E+01
GO_BP_FAT GO:0022403,cell cycle phase 3 7.93E-03 1.83E+01
GO_BP_FAT GO:0022402,cell cycle process 3 9.62E-03 1.66E+01
GO_BP_FAT GO:0051301,cell division 3 1.15E-02 1.52E+01
GO_BP_FAT GO:0007049,cell cycle 3 2.02E-02 1.14E+01
KEGG_PATHWAY cfa04110:Cell cycle 27 1.14E-20 1.06E+01
KEGG_PATHWAY cfa03030:DNA replication 11 9.04E-10 1.50E+01
KEGG_PATHWAY cfa04114:Oocyte meiosis 12 3.70E-06 5.88E+00
KEGG_PATHWAY cfa04914:Progesterone-mediated oocyte maturation 9 1.41E-04 5.67E+00
KEGG_PATHWAY cfa04115:p53 signaling pathway 8 1.75E-04 6.49E+00
KEGG_PATHWAY cfa03420:Nucleotide excision repair 6 2.19E-03 6.33E+00
KEGG_PATHWAY cfa00240:Pyrimidine metabolism 7 6.36E-03 4.10E+00
KEGG_PATHWAY cfa00100:Steroid biosynthesis 4 6.69E-03 9.92E+00
GO, Gene Ontology; BP: Biological Process; p value: modified Fisher exact P value calculated by DAVID software;
Fold Enrichment defined as the ratio of the two proportions: input genes involved in a biological process and the background information.
doi:10.1371/journal.pone.0095481.t002
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unpaired test was implemented in the program SAM (Significance
Analysis of Microarrays) release 4.0 [25], enforcing a False
Discovery Rate (FDR) of 1% and a –fold change (FC) of 2.
Gene expression data from 51 MCTs were analyzed to evaluate
the ability to classify MCT samples with a reduced set of
informative markers, by using a statistical approach for class
prediction implemented in the Prediction Analysis of Microarrays
(PAM) software, available online at http://www-stat.stanford.edu/
,tibs/PAM. This software uses the method of nearest shrunken
centroids to find out the minimal set of genes that provides the
greatest accuracy of class prediction. The program first performs a
discriminant analysis on ‘‘known’’ samples (Training Sample Set,
in this study these known samples were the 18 reference samples as
previously described) to choose the smallest panel of genes
providing the greatest accuracy of class prediction with the
smallest misclassification error. Subsequently, the program uses
the same panel of genes to predict a class for a set of ‘‘unknown’’
samples (in this study represented by 33 of 51 MCTs, for whose
grading the pathologists did not reach a consensus).
To confirm the correct choice of reference samples and PAM
class prediction results, hierarchical clustering (HCL) and principal
component analysis (PCA) on gene expression data were carried
out by using the TMEV suite.
All other statistical tests (linear regression, non-parametric
Spearman correlation analysis and Mann-Whitney test) were
carried out with the GraphPad Prism 5 software (San Diego, CA,
USA). Statistical significance was set at p,0.05.
Functional Annotation
The functional annotation analysis of differentially transcribed
genes was performed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) web-server
v.6.7 (http://david.abcc.ncifcrf.gov) [26]. Gene ontology (GO)
terms and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways included in the DAVID knowledgebase were consid-
ered. The following parameters were respectively used for GO
Biological Process and KEGG pathways: gene count 3, ease 0.05;
gene count 4, ease 0.05.
Quantitative Real Time PCR (qPCR)
Thirteen target genes selected through class prediction analysis
and three internal control genes (ICGs) were chosen for qPCR
amplification. For each transcript, gene-specific primers that
encompassed one intron and the most appropriate UPL probe
were designed by using the Universal Probe Library (UPL) Assay
Design Centre web service (Roche Diagnostics, Mannheim,
Germany). Putative intron-exon boundaries were inferred from
the UCSC Genome Browser and Ensembl Genome Browser
Databases (http://genome.ucsc.edu and www.ensembl.org).
First-strand cDNA was synthesized from 1 mg of total RNA
using the High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Carlsbad, CA) according to the manufacturer’s
protocol and stored at 220uC until use. Primers specificity was
evaluated either in silico by means of the BLAST tool than
experimentally by Power SYBR Green I (Life Technologies,
Carlsbad, CA) amplification and melting curve analysis. qPCR
reactions (10 mL final volume) consisted of 1X LightCycler 480
Probe Master (Roche Applied Science, Indianapolis, IN), 300 or
600 nM forward and reverse primers (Eurofins MWG Operon,
Ebersberg, Germany) according to the assay set-up, 200 nM
human UPL probe and 2.5 mL of 1:100 diluted cDNA. qPCR
analysis was performed in duplicate in a LightCycler 480
Instrument (Roche Applied Science, Indianapolis, IN) using
standard PCR conditions (an activation step at 95uC for 10
minutes; 45 cycles at 95uC for 10 seconds and at 60uC for 30
seconds; a cooling step at 40uC for 30 seconds) and LightCycler
480 clear plates (Roche Applied Science, Indianapolis, IN). No-
template controls and no-reverse transcription controls were
included on each plate. Calibration curves, using a 3-fold serial
dilution of a cDNA pool, were performed. ICGs assay parameters
were comparable to that of the target genes; moreover, no
statistically significant differences were observed in their expression
profile between differentiated and undifferentiated MCT samples.
Data were analyzed with the LightCycler480 software release
1.5.0 (Roche Applied Science, Indianapolis, IN) by using the
second derivative method. Messenger RNA relative quantification
was performed by using the DDCt method [27], the arithmetic
mean of the three selected ICGs and a cDNA pool comprehending
two external MCT samples as calibrator.
Twenty-two MCT samples not processed on the array were
chosen for qPCR confirmatory analysis. All thirteen transcripts
selected with class prediction analysis (PAM analysis) were
amplified in duplicate as reported above. RQ values were finally
analyzed by using Multid-Genex software [28]. Clustering and
PCA were performed, adopting the following setting: mean center
scaling, Ward’s algorithm and Manhattan distance.
Survival Analysis
Survival time was defined as the interval from date of surgery to
death and was investigated by means of Kaplan–Meier survival
analysis, stratified by MCT molecular classification (differentiated
and undifferentiated MCTs). The log rank test was used to
compare survival time between groups.
For each selected target gene, a receiver-operator characteristic
(ROC) curve was created. For areas under curve .0.5, the cut-off
value (in terms of relative quantification value, RQ) that better
discriminated MCT associated with patient mortality was deter-
mined. On the basis of the chosen cut-off value, sensitivity and
specificity parameters, with 95% confidence intervals, were
calculated. All statistical tests were carried out in GraphPad Prism
5 software (San Diego, CA, USA). Statistical significance was set at
p,0.05.
Results
Animals
Dogs characteristics are shown in Table S1, including the 2
population subsets (GEP cohort, n = 51, and dogs not on array,
n = 22). Histological grading and mitotic index of reference
samples used for class prediction analysis are shown in Table
S2. All included dogs received some form of treatment, consisting
of surgery (n = 54), surgery and systemic treatment (n = 12),
radiation therapy and systemic treatment (n = 3), systemic
treatment (n = 3), and a combination of surgery, radiation therapy
and systemic treatment (n = 1).
DNA Microarray Validation
DNA microarray experiments were individually performed in
51 MCT samples, characterized by a RIN$7. Technical replicates
(labeling and hybridization) were conducted for 4 samples
arbitrarily chosen. Linear regression analysis of the entire dataset
for each technical replicate revealed a r2 ranging between 0.973
and 0.993 with a p,0.001. Non parametric Spearman correlation
analysis of all samples considering RQ values obtained by qPCR
target gene amplification and corresponding normalized DNA
microarray data showed positive and significant results for all
validated genes (Table 1).
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Gene Expression Profiling of Reference Samples
The transcriptome of reference samples, e.g., differentiated
(n = 13) and undifferentiated (n = 5) MCT samples was compared
by using the SAM program. The unpaired t-test with FDR of 1%
and FC of 2 revealed a total of 597 differentially expressed genes
(DEGs, 147 down-regulated and 450 up-regulated). The complete
list of DEGs and corresponding FC is reported in Tables S3–S4.
To explore the functional significance of the observed differences,
enrichment analysis of up- and down-regulated genes was carried
out by using GO Biological Processes and KEGG Pathways
analysis through DAVID web-server. Among the 597 DEGs, only
352 had a unique gene identity that could be assigned to GO
Biological Process and KEGG Pathway. The following GO
Biological Processes were found to be differentially regulated: M-
phase, cell cycle phase, cell cycle process, cell division and cell
cycle (Table 2). The GO Biological Process definition for DEGs
partially reflected what was described for KEGG pathways: cell
cycle, DNA replication, oocyte meiosis, progesterone-mediated
oocyte maturation, p53 signaling pathway, nucleotide excision
repair, pyrimidine metabolism and steroid biosynthesis.
DEGs dataset obtained through the transcriptome comparison
of differentiated and undifferentiated reference samples was
analyzed by HCL and PCA. Both HCL tree and PCA clearly
identified, without overlapping, two main groups, being attribut-
able to differentiated and undifferentiated reference samples
(Figures 1–2). The first three components accounted for a
substantial fraction (79.883%) of the total variance. This result
confirmed that the samples chosen as reference samples were good
as Training Sample Test for class prediction analysis.
Class Prediction Analysis
Gene expression data from all 51 MCT samples were analyzed
to evaluate the ability to classify ‘‘unknown’’ samples with a
reduced set of informative markers. Differentiated and undiffer-
entiated reference MCTs were used as ‘‘known’’ samples. The
nearest shrunken centroid analysis implemented in the PAM
program was effective in discriminating between differentiated and
undifferentiated reference samples with a 100% accuracy
(misclassification error of 0), thereby selecting 13 transcripts. This
minimal gene set was then used in the cross-validation procedure
yielding a probability of correct identification (about 100%) for all
33 remaining samples (Figure 3). The class prediction analysis
allowed the identification, among the unknown samples, of a total
of 7 undifferentiated and 26 differentiated MCTs.
The magnitude and pattern of gene expression of selected
transcripts are represented in Figure 4. The heat map comparing
the two groups displayed relatively consistent alterations in gene
expression between the two categories. The statistical approach
(PCA of all 51 MCT samples restricted to gene expression data of
the 13 selected genes) confirmed this result. In details, the first
three components, accounting for 99.924% of the total variance,
identified two groups. The x-axis, explaining almost all the
variance (99.746%), separated samples referable to the two
identified categories (Figure 5).
qPCR Analysis
The mRNA expression of the 13 target genes was finally
evaluated by qPCR. A complete list of the thirteen selected target
genes and the three ICGs (including sequences IDs used for primer
design, primer pair sequences, probes and amplicon size) is
presented in Table S5. Calibration curves revealed a PCR
efficiency comprised in the range of acceptability (90–110%), an
error value ,0.2 and a dynamic range .9 cycles (except for
centromere protein P (CENPP), characterized by a dynamic range
of 6 cycles: Table S6). Table 3 showed the relative quantification
values of each target gene in the 39 differentiated and 12
undifferentiated samples. Except for gelsolin (GSN), that was
significantly down-regulated in undifferentiated group, all remain-
ing target genes were significantly up-regulated (p,0.001) from
about 2- up to 7-fold in undifferentiated MCTs. Spearman
correlation analysis between FC obtained through DNA micro-
array and qPCR analysis was statistically significant (Spearman
r= 0.88, p,0.001).
Survival Analysis
The molecular classification into differentiated and undifferen-
tiated MCTs was considered as stratification variable for a survival
time analysis (Figure 6). Differentiated MCTs showed a survival
probability of 94% after 12 months, stabilizing at 90% after 15
months. Undifferentiated MCTs survival probability stabilized at
50% after 13 months. The survival curves of differentiated and
undifferentiated samples were significantly different (p=0.0026).
To understand whether the target gene modulation was
associated with an increased incidence of MCT-related mortality,
ROC curve analysis was performed for each target. A significant
association with MCT-related mortality was evidenced for Fork-
head box M1 (FOXM1), GSN, Flap structure specific endonucle-
ase 1 (FEN1) and Karyopherin alpha 2 (KPNA2). Specifically, the
area under the ROC curve (AUC) for FOXM1 gene showed a
value of 0.79 (95% CI: 0.60–0.98), and this one estimated the test
global performance. By using the cut-off of 0.5540 arbitrary units
(AU, RQ value), test sensitivity and the specificity were 87.5%
(95% CI, 47.35% –99.68%) and 62.79% (95% CI, 46.72% –
77.02%), respectively. Overall, 1 out of 28 cases with FOXM1,
0.5540 AU and 7 out of 23 cases with FOXM1.0.5540 AU died
because of MCT. With a RQ value ,0.5540 AU the survival
probability stabilized at 94% after 15 months, whereas for a RQ
value .0.5540 AU the survival probability was 67% after 13
months. The two survival curves significantly differed (p=0.0092:
Figure 7A). About GSN, the best cut-off value was 3.749 AU
(AUC: 0.74; 95% CI, 0.53–0.96), with a sensitivity of 75.0% (95%
CI, 34.91%–96.81%) and a specificity of 67.44% (95% CI,
51.46%–80.92%). On the whole, 2 out of 31 cases with GSN .
3.749 AU and 6 out of 20 cases with GSN ,3.749 AU died of
MCT. With a RQ value .3.749 AU the survival probability
stabilized at 92% after 15 months, while with a RQ value ,3.749
AU the survival probability was 65% after 13 months. The two
survival curves were significantly different (p=0.0147: Figure 7B).
The AUC value for FEN1 was 0.72 (95% CI, 0.51–0.93). By using
a cut-off of 0.8155 AU, the test sensitivity and specificity were
75.0% (95% CI, 34.91% –96.81%) and 69.77% (95% CI, 53.87%
–82.82%), respectively. Overall, 2 out of 33 cases with FEN1,
0.8155 AU and 6 out of 18 cases with FEN1.0.8155 AU died
because of MCT. The survival probability with RQ ,0.8155 was
96% after 12 months and stabilized at 92% after 15 months,
whereas with RQ .0.8155 was 68% after 9 months and stabilized
at 61% after 13 months. The two survival curves significantly
differed (p=0.0037: Figure 7C). Finally, the best identified cut-off
value for KPNA2 was 0.4823 AU (AUC: 0.82; 95% CI, 0.65–
0.99), with sensitivity and specificity of 87.5% (95% CI, 47.35%–
99.68%) and 69.77% (95% CI, 53.87%–82.82%), respectively.
Overall, 1 out of 31 cases with KPNA2,0.4823 AU and 7 out of
20 cases with KPNA2.0.4823 AU died because of MCT. With a
RQ value ,0.4823 the survival probability stabilized at 97% after
5 months, while with a RQ value .0.4823 the survival probability
was 60% after 15 months. Even in this case, the two survival
curves were significantly different (p=0.0024: Figure 7D).
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qPCR Confirmatory Analysis
The potential use of a simplified gene expression profile that
could be translated into a diagnostic platform to rapidly and
accurately distinguish between differentiated and undifferentiated
MCTs was finally evaluated. This step of validation consisted in
the evaluation of the gene expression profiling of the 13 selected
transcripts, by using a qPCR approach, in an independent cohort
of 22 MCT samples. This step permitted to verify their utility to
provide a molecular classification being independent from classical
histological grading. Tumor samples were graded by pathologists
who were unaware of the molecular results. Follow up data were
also collected for each case.
Data collected from qPCR analysis were analyzed by using the
MultiD-Genex software. Clustering and PCA results are reported
in Figure 8A–B. In PCA, the first two principal components
accounted for 71.32% of the total variance. Both analyses showed
the separation of samples into two main groups named Group 1
and 2, referable to differentiated and undifferentiated MCTs,
respectively. Particularly, if we consider the histological grading,
Group 1 (differentiated, n = 14) consisted of 7 Patnaik-G1 and G2
or 14 Kiupel L cases while Group 2 (undifferentiated, n= 8)
Figure 1. Hierarchical clustering and heat map of differentiated and undifferentiated reference samples. Hierarchical clustering was
performed using gene expression data of 597 differentially expressed genes obtained through the comparison of reference samples (13
differentiated and 5 undifferentiated mast cell tumors) with SAM, fixing a fold change of 2 as well as a False Discovery Rate of 0.01 as parameters. Red
and green indicates up- and down-regulated genes relative to the mean expression in all samples, respectively. Samples were hierarchically clustered
into differentiated (left, yellow) and undifferentiated (right, red) and based on the Pearson correlation coefficients and average linkage clustering.
Genes were hierarchically clustered based on Pearson correlation coefficients and average linkage clustering. Units of the bar legend: absolute values.
doi:10.1371/journal.pone.0095481.g001
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consisted of 2 Patnaik-G1, 4 G2, 2 G3 or 5 Kiupel L and 3 H
MCTs. By considering the outcome (dogs dead for MCT are
indicated in red), in Group 2 50% of cases died for MCT, while in
Group 1 only one case died during the follow up for MCT-
unrelated causes; therefore it was not considered in the survival
analysis (Figure 8C). The comparison of the two survival curves
yielded a statistically significant difference (p=0.0018); the survival
probability of Group 2 stabilized at 38% after 5 months.
Discussion
The transcriptome of canine mammary tumor, hemangiosar-
coma, osteosarcoma, lymphoma, urinary bladder cancer, histio-
cytic sarcoma and melanoma has been recently characterized by
using a DNA microarray approach
[3,4,5,6,7,8,9,10,11,12,13,14,15].
To the best of authors’ knowledge, with the exception of a
recent study comparing the proteome of 5 Kiupel L and 5 H
MCTs [29], this is the first report focusing on the molecular
characterization of canine MCT. Its importance in veterinary
medicine is due not only to the high tumor frequency, but also to
the highly variable biological behavior, often difficult to be
predicted [16,30].
In this scenario, we analyzed the transcriptome of 51 canine
primary cutaneous MCTs aiming at identifying a gene signature of
MCT aggressiveness and predicting a priori its biological behavior.
The primary objective of this study was to provide a basis for the
development of a simple diagnostic platform that could rapidly
and accurately distinguish between differentiated and undifferen-
tiated MCTs and support the histological grading, whose
prognostic value is still questionable. Such a tool might be of
great value to diagnose and treat MCT. Additionally, pet owners
would greatly benefit from a more accurate survival time
expectance when weighing their dog’s quality of life and their
own monetary obligations in treatment decisions. Finally, the
analysis of gene signature may allow the elucidation of either a
single gene or a gene network that may be manipulated for
treatment purposes.
To this aim, we performed preliminary HCL and PCA
investigations by using the whole dataset (all informative genes)
obtained by microarray analysis, but the extreme variability
observed among the 51 samples tested did not permit to clearly
separate samples into well-defined groups. Indeed, the sum of the
first 2 principal components accounted for less than 30% of the
total variance (data not shown). Thus, to define a reduced
transcriptional profile permitting a better category assignment, we
decided to use differentially expressed genes among the categories
assigned by histological grading. Accordingly, the transcriptome
was compared among Patnaik-G1, G2 and G3 MCTs and
between Kiupel L and H MCTs by using SAM tool. In the first
case, no differentially expressed genes were observed, due either to
the high variability among samples or the imprecise/subjective
grading. In the second case, a set of differentially expressed genes
was observed, but the resulting PCA evidenced two partially
overlapped categories (data not shown). The failure of these
approaches prompted us to use an alternative approach, consisting
in the choice of known reference samples to be used in class
prediction analysis.
The choice of MCT cases to be used as known samples was
based on histological criteria (2-tier histologic grading system and
mitotic index) that permitted to obtain a 100% concordance
among all pathologists. Statistical analysis of microarray data
supported the choice and confirmed that reference samples
belonged to two distinct categories.
Pathways analysis of DEGs revealed that cell cycle, DNA
replication, nucleotide excision repair, p53 signaling pathway and
pyrimidine metabolism were among the pathways deregulated in
undifferentiated MCTs compared to well differentiated MCTs. In
particular, our data highlights pathways that are important in rate
of proliferation, malignant transformation, response to DNA
damage and nucleotide metabolism. An altered expression of
genes within these functional categories has been previously
reported in the literature for other solid tumors, and these genes
properly characterized the tumor when compared to its normal
counterparts [3,7]. In addition, the cell-cycle signature has been
described to be useful to stratify canine and human osteosarcomas
according to their biological behavior in vivo [10].
The class prediction analysis identified a set of 13 transcripts
involved in malignant transformation that were able to accurately
separate MCT samples into differentiated and undifferentiated
ones. This panel of genes did not match with the proteins recently
identified by using a proteomic approach. In this latter study, 5
Kiupel L and 5 H MCTs were compared, and in H MCTs a
modulation of four stress response proteins (HSPA9, PDIA3,
TCP1A and TCP1E) as well as of proteins mostly associated with
cell motility and metastasis (WDR1, ACTR3, ANXA6, ANXA2,
ACTB and transferrin) was observed [29]. Conversely, most genes
here identified are coordinately regulated during mitosis [31,32]
and/or are part of the DNA damage checkpoint. Cell cycle
pathway is in fact often deregulated in cancer during malignant
transformation, and the increased DNA repair gene expression is
most likely a consequence of increased DNA replication. As an
Figure 2. Principal component analysis of differentiated and
undifferentiated reference samples. Analysis was performed using
gene expression data of 597 differentially expressed genes obtained
through the comparison of reference samples (13 differentiated and 5
undifferentiated mast cell tumors) with SAM, fixing a fold change of 2 as
well as a False Discovery Rate of 0.01 as parameters. Each colored
sphere corresponds to a reference sample (differentiated mast cell
tumors are indicated in yellow, while undifferentiated ones in red). The
value of each principal component is reported on the graph. The sum of
the three principal components accounted to the 79.883% of the total
variance.
doi:10.1371/journal.pone.0095481.g002
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Figure 3. Class prediction analysis. Plot of cross-validated probabilities and test probabilities for sample classification. (A) On x-axis individual
reference samples: 1–5 undifferentiated mast cell tumor samples, 6–18 differentiated mast cell tumor samples; on y-axis the probability of being
classified as undifferentiated (blue rhombus) or differentiated (red squares). (B) On x-axis individual unknown samples; the probability of being
classified as undifferentiated (blue rhombus) or differentiated (red squares).
doi:10.1371/journal.pone.0095481.g003
Figure 4. Gene expression profiling of marker genes in differentiated and undifferentiated MCT samples. Heat map and hierarchical
clustering of all samples analyzed by DNA microarray using probes referable to the transcripts identified by class prediction analysis. Red indicates up-
regulated and green down-regulated genes relative to the mean expression in all samples. For display purposes, samples in each class (differentiated
and undifferentiated) were clustered separately and arranged from differentiated (left, yellow) to undifferentiated (right, red). Genes were
hierarchically clustered separately based on the Pearson correlation coefficients and average linkage clustering. Units of the bar legend: absolute
values.
doi:10.1371/journal.pone.0095481.g004
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example, pathways as cell cycle checkpoint, mitosis, spindle cell
genes and DNA repair were found to be commonly up-regulated
in canine mammary tumor and human breast cancer [5]. Most of
the genes here identified for their over-expression in undifferen-
tiated MCTs are involved in cell cycle and are described below.
Cyclin B2 (CCNB2) has a function at the transition from G2 to
mitosis. Experimental evidence suggested that CCNB2 promoter
activity is down-regulated by tumor suppressor p53 gene [33] and
it may function as an oncogene [34]. An over-expression of this
gene has been previously observed in human cervical cancer,
invasive breast carcinoma, human astrocytoma, human pituitary
adenoma, and canine osteosarcoma [31,34,35,36,10]; in addition,
the relative expression of serum circulating CCNB2 mRNA in
human cancer patients was significantly higher than in normal
controls and benign disease group, and significantly correlated
with cancer stage and metastasis status. Thus, it may have
potential clinical applications in screening and monitoring of
metastasis and therapeutic treatments [37].
The Forkhead box M1 (FOXM1) is an oncogenic transcription
factor of the Forkhead family, whose expression is excluded in
quiescent or differentiated cells, but highly elevated in proliferating
and malignant cells [38]. FOXM1 is over-expressed in a variety of
human tumors and plays a critical role in cancer development and
progression [38].
Cell division cycle 20 homolog (CDC20) promotes spindle
assembly checkpoint-mediated mitotic arrest through the mitotic
checkpoint complex, induces apoptosis through degradation of
anti-apoptotic proteins and triggers mitotic exit through CCNB
Figure 5. Principal component analysis of array-processed
samples using marker gene data. Each colored sphere corresponds
to an individual sample classified by PAM analysis (differentiated mast
cell tumors are indicated in yellow, while undifferentiated ones in red).
The value of each principal component is reported on the graph. The
sum of the three principal components accounted to the 99.924% of
the total variance.
doi:10.1371/journal.pone.0095481.g005
Table 3. Target genes mRNA expression in differentiated and undifferentiated MCT samples.
Target genes qPCR results (RQ values ± SD)
Differentiated MCTs (n=39) Undifferentiated MCTs (n=12) p value FC
CCNB2 0.2560.18 0.9760.28 p,0.001 3.88
CDC20 1.8461.22 6.1562.93 p,0.001 3.34
CDCA8 0.4160.21 1.1360.38 p,0.001 2.76
CENPP 0.5860.24 1.0960.34 p,0.001 1.88
FEN1 0.7060.18 1.3060.59 p,0.001 1.86
FOXM1 0.4960.20 1.7161.25 p,0.001 3.49
GSN 5.8062.39 1.9961.20 p,0.001 0.34
KPNA2 0.4360.10 0.7860.27 p,0.001 1.81
NUF2 0.3960.23 2.7662.57 p,0.001 7.08
NUSAP1 0.2960.09 0.7460.36 p,0.001 2.55
PRC1 0.4360.28 2.0561.11 p,0.001 4.77
RAD51 0.2260.10 0.7360.20 p,0.001 3.32
UBE2S 0.7460.19 1.4760.63 p,0.001 1.99
Data are expressed in arbitrary units. FC: -fold change.
doi:10.1371/journal.pone.0095481.t003
Figure 6. Survival curve of differentiated vs. undifferentiated
mast cell tumors. Kaplan-Meyer survival plot stratified by molecular
classification (differentiated and undifferentiated MCTs).
doi:10.1371/journal.pone.0095481.g006
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degradation [39]. Recent studies have shown that CDC20 may
function as an oncoprotein, promoting the development and
progression of human cancers [40]. Results here obtained are in
accordance with human literature, where an up-regulation of this
gene was observed in cervical cancer, primary non-small cell lung
cancer, pancreatic ductal adenocarcinoma, urothelial bladder
cancer and colorectal cancer, too [31,41,42,43,44]; therefore, it
may serve as a potential prognostic biomarker, as already
described in human oncology.
Cell division cycle associated protein 8 (CDCA8) is a
component of the chromosomal passenger complex (CPC), a
complex that acts as a key regulator of mitosis. The CPC complex
has essential functions at the centromere in ensuring correct
chromosome alignment and segregation and is required for
chromatin-induced microtubule stabilization and spindle assem-
bly. It exhibited frequent and robust up-regulation in cervical
cancer and chemoresistant ovarian cancer [45,46].
NUF2 (NDC80 kinetochore complex component, homolog) or
CDCA1 (cell division cycle associated protein 1) is another
component of the essential kinetochore-associated NDC80 com-
plex, which is required for chromosome segregation and spindle
checkpoint activity during mitosis. An over-expression of this
transcript has been previously observed in colorectal and gastric
cancers, as well as in serous adenocarcinomas [47,48]. The
silencing of this gene through RNA interference leads to increased
apoptosis [48], and suggests that its expressional control could be
utilized for molecular target therapy in patients affected by
colorectal and gastric carcinoma [47].
Nucleolar and spindle-associated protein 1 (NUSAP1) plays a
role in spindle microtubule organization. An over-expression of
this gene has been reported in cervical cancer, grade III versus
grade I meningioma, in recurrent prostate cancer after radical
prostatectomy and breast cancer [31,49,50,51]. It has been also
suggested as an early molecular marker of ductal carcinoma in situ
and invasive carcinoma [51] and as a prognostic factor in
metastatic melanoma where it is negatively associated with survival
[52].
Protein Regulator of Cytokinesis 1 (PRC1) is present at high
levels during the S and G2/M phases of mitosis but its levels drop
dramatically when the cell exits mitosis and enters the G1 phase.
Further than its role in human cervical cancer [31], it has been
recognized as a therapeutic gene for its cancer-specific over-
expression in breast cancer cell lines and patient tissues [53].
Centromere protein P (CENPP) is a novel centromere protein
that has an important role during interphase of cell cycle and it is
required for proper kinetochore function and mitotic progression
[55]. An overexpression of centromere proteins has been observed
in various types of human cancers and was significantly correlated
with tumor grade and survival [54,55,56,57,58].
Ubiquitin-conjugating enzyme E2S (UBE2S) gene encodes a
member of the ubiquitin-conjugating enzyme family that works
with the anaphase-promoting complex ubiquitin ligase ubiquity-
lating protein substrates whose degradation regulates progress
through mitosis [59]. In a recent work in breast cancer [60]
authors identified, through weighted gene co-expression network
analysis, a cluster of proliferation-related genes including UBE2S
Figure 7. Survival curves for mortality due to mast cell tumor, stratified by marker gene mRNA expression cut point. (A) FOXM1. The
cut-off chosen was 0.5540 AU (FOXM1,0.5540 AU: n = 28; FOXM1.0.5540 AU: n = 23). (B) GSN. The cut-off chosen was 3.749 AU (GSN.3.749: n = 31;
GSN ,3.749 AU: n = 20). (C) FEN1. The cut-off chosen was 0.8155 AU (FEN1,0.8155 AU: n = 33; FEN1.0.8155 AU: n = 18). (D) KPNA2. The cut-off
chosen was 0.4823 AU (KPNA2,0.4823 AU: n = 31; KPNA2.0.4823 AU: n = 20).
doi:10.1371/journal.pone.0095481.g007
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that, when up-regulated, were correlated to increased tumor grade
and were associated with poor survival.
The last gene belonging to mitosis pathway, namely GSN, was
the only gene down-regulated in undifferentiated MCTs. It has
been reported to be an onco-suppressor participating in the
regulation of the apoptotic process and interacting with p53 [61].
Its over-expression causes cell cycle arrest or delay at the G2/M
phase of the cell cycle and inhibition of tumor growth, as
demonstrated in an orthotopic bladder cancer nude mouse model
[62]. GSN is down-regulated in human breast cancer tissues
compared to controls and its transcript level is linked with
metastasis development and death [63]. Furthermore, GSN has
been proposed as serum biomarker and potential target for gene
therapy in human osteosarcoma [64].
Other two potential markers, Flap endonuclease 1 (FEN1) and
RAD51 are involved in DNA repair pathway. FEN1 is a structure-
specific endonuclease best known for its critical roles in Okazaki
fragment maturation, DNA repair and apoptosis-induced DNA
fragmentation [65]. It plays an essential role in maintaining
genomic stability and preventing tumorigenesis, thus acting as a
tumor suppressor [66]. FEN1 is significantly up-regulated in
multiple human cancers and its aberrant expression in tumor cells
is associated with hypomethylation of the CpG islands within the
FEN1 promoter [67].
RAD51 protein plays a key role in homologous recombination.
It has been shown to be up-regulated in many human cancers,
especially higher grade, chemoresistant and radioresistant tumors
[68]. Expression is tightly regulated in normal cells, with
dysregulation leading to genomic instability and possibly contrib-
uting to oncogenesis [68]. RAD51 mRNA amount was increased
in laser-microdissected mammary simple carcinomas when com-
pared to adenomas or non neoplastic mammary gland of the same
dog, indicating a genomic instability in RAD51-expressing cells in
carcinomas [69,70].
Finally, Karyopherin a 2 (KPNA2) has recently emerged as a
potential biomarker in multiple human cancer forms [71]. Owing
to its role in nucleocytoplasmic transport, where it mediates the
translocation of a multitude of proteins, KPNA2 is involved in
many cellular processes [72]. The aberrant high levels observed in
human cancer tissue (i.e., gastric adenocarcinoma and epithelial
ovarian cancer) have been associated with poor prognosis,
prompting the idea that KPNA2 plays a role in carcinogenesis
[73,74]. Studies in cancer cells demonstrated that KPNA2
deregulation affects malignant transformation, thus it was consid-
ered a potentially relevant therapeutic target [72].
Molecular pathology, a scientific approach defining cancer
subtypes based on the underlying molecular footprints, has led to
the discovery of subtypes in several different tumors. Nevertheless,
it has been demonstrated that this approach works at its best when
cancer subtypes based on genetic profiles are already known:
whenever the different subtypes of the same cancer and the
number of patients belonging to each of them are known, then a
statistical model could be built to associate a specific gene
expression profiling, typical of a subtype of cancer, to an individual
patient [75]. In the present study, the approach of using well
known histological categories did not produce useful results; thus,
an alternative approach consisting of a predictive analysis was
used. Alternative statistical methods to identify subtypes exist, but
they can generate classifications that lack clinical relevance [75].
Nevertheless, in the present work we were able to separate MCTs
in two molecular subtypes that did not perfectly match with
Patnaik-G1, G2, G3 or Kiupel L and H grades, defined by
conventional histological grading. Conversely, they referred to
differentiated and undifferentiated MCTs, whose prognosis was
largely documented in the literature [76] and here confirmed by
survival analysis.
Meanwhile, presented results confirmed the usefulness of a
transcriptomic approach in the definition of a signature that could
segregate molecular subtypes of the same tumor with different
survival probabilities [3,10,77]. Thus, the molecular classification
coupled with the histological grading, universally recognized as a
reference for MCT prognosis prediction but still presenting some
gaps (i.e., Patnaik-G2 MCT), might permit a better characteriza-
tion of the biologic behavior of the tumor.
As genome-wide gene expression profiling is cost-prohibitive
and impractical, we selected 13 simple qPCR assays to stratify
MCTs into differentiated and undifferentiated cases. The reliabil-
ity of the gene set was tested, by means of a qPCR approach, upon
a separate cohort of MCT samples for which a complete follow up
was available. Even in this case, we observed a statistical significant
association between molecular classification and survival time,
confirming the potential usefulness of these results to develop a
rapid and relatively cheap benchtop diagnostic test based on the
expression of 13 genes that can classify canine MCTs into one of
these 2 subgroups, and enabling a direct clinical application of our
results. Worth mentioning, in veterinary medicine a benchtop
diagnostic test composed of 4 genes has been previously proposed
for canine lymphoma [11].
As a whole, this study allowed us to fill a gap in the tumor
understanding and it contributed to the uncertainty about the
relevance and utility of morphological classification systems. In
addition, the transcripts here identified not only may predict
prognosis (relative quantification values were significantly associ-
ated with poor survival), but may also be selected as future targets
for therapy (gene therapy or chemotherapy), as previously
reported in various human cancers [37,47,53,64,72].
In the future, a study population with a larger sample set of
tumors might provide a more robust basis to confirm and refine
segregation between differentiated and undifferentiated MCTs.
Conclusions
In conclusion, the transcriptome of canine cutaneous MCT was
characterized for the first time by using a DNA microarray
approach. Data obtained allowed the identification of a signature
of aggressiveness in canine MCT; particularly, a set of 13 potential
biomarkers identified through a class prediction analysis segregat-
ed MCT samples into two distinct molecular categories, namely
differentiated and undifferentiated MCTs. The molecular classi-
fication into differentiated and undifferentiated MCTs as well as
the mRNA expression of FOXM1, GSN, FEN1 and KPNA2 were
significantly associated with survival. The prognostic value of the
Figure 8. qPCR confirmatory analysis. Marker genes identified by class prediction analysis were amplified in an independent cohort of 22 mast
cell tumors in order to comprehend their utility for mast cell tumor classification. Clustering analysis and PCA of gene expression data were
performed using MultiD-Genex software for qPCR data, using the following settings: mean center scaling, Ward’s algorithm and Manhattan distance.
(A) Clustering tree and (B) principal component analysis of independent mast cell tumor samples. Cases characterized by MCT-related death are
indicated in red. The two groups identified are named group 1 and 2 (differentiated and undifferentiated MCTs, respectively). (C) Kaplan-Meyer
survival plot stratified by molecular classification (group 1 and 2).
doi:10.1371/journal.pone.0095481.g008
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molecular classification was also confirmed in a separate cohort of
MCT cases, for which an accurate follow up was available. Thus,
this set of genes could be useful to develop a benchtop diagnostic
test that could support canine MCT histological grading and
consequently having prognostic relevance. Finally, analysis of gene
signature allowed elucidation of single genes or genetic pathways
(mitosis and DNA repair), which could be considered for future
diagnostic and treatment purposes as already performed in human
oncology.
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